Skip to main content
. Author manuscript; available in PMC: 2013 Oct 15.
Published in final edited form as: Int J Pharm. 2012 Jun 9;436(1-2):127–134. doi: 10.1016/j.ijpharm.2012.05.038

Table 3.

Plasma and brain pharmacokinetic parameters obtained by noncompartmental analysis of the concentration-time profile data after an i.v. bolus dose of pazopanib in absence and presence of elacridar (GF120918) in FVB wild type mice.

PK parameters Pazopanib alone
Pazopanib + GF120918
Plasma Brain Plasma Brain
λz(h−1) 0.50 0.37 0.38 0.25
Half-life (h) 1.39 1.89 1.83 2.75
Clearance (ml/min/kg) 2.38 2.49
Volume of distribution (ml/kg) 285.86 398.22
AUC (0 → tlast) (mg min/ml) 1.356 ± 0.043 0.020 ± 0.001 1.029 ± 0.071 0.042 ± 0.003
AUC (0 → tlast) brain/AUC (0 → tlast) plasma 0.015 0.041